Loading chat...

IN SR0112

Resolution

Official Source

Status

Passed

4/26/2013

Primary Sponsor

Patricia Miller

Click for details

Origin

Senate

2013 Regular Session

AI Summary

  • Urges the legislative council to assign the topic of biosimilar biological products to the Health Finance Commission for study

  • Defines a biosimilar biological product as a biological product licensed under federal law that is highly similar to a reference product with no clinically meaningful differences in safety, purity, and potency

  • States that Indiana should study how state law may affect prescribing and substituting of biosimilar biological products for other drugs

Legislative Description

Health Finance Commission to study biosimilar biological products.

Last Action

First reading: adopted voice vote

4/26/2013

Full Bill Text

No bill text available